Shih-Ta Chen

Title: Shih-Ta Chen: Innovator in Cancer Treatment Technologies

Introduction

Shih-Ta Chen is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of cancer treatment through his innovative patents. With a total of 2 patents, Chen is recognized for his work in developing advanced therapeutic methods.

Latest Patents

One of Chen's latest patents is titled "Nucleic acid-drug complex and use thereof." This invention provides a nucleic acid-drug complex that includes a nucleic acid sequence of an anti-PD-L1 aptamer and a CpG oligonucleotide sequence capable of activating TLR9. The complex is designed to enhance the efficacy of cancer treatments by utilizing a specific combination of nucleic acid sequences.

Another notable patent is "Intralymphatic delivery of hyaluronan nanoparticle for cancer metastasis." This patent discloses a method for treating lymphatic cancer using hyaluronan nanoparticles. These nanoparticles consist of a hyaluronic acid derivative and a platinum compound, offering significant advantages in the delivery of platinum-based medicines for lymphatic cancer treatment.

Career Highlights

Shih-Ta Chen is affiliated with the Industrial Technology Research Institute, where he continues to advance research in cancer therapies. His work is characterized by a commitment to developing innovative solutions that address critical health challenges.

Collaborations

Chen collaborates with esteemed colleagues, including Ping-Fu Cheng and Ya-Ling Chiu, who contribute to his research endeavors. Their combined expertise enhances the potential impact of their innovations in the medical field.

Conclusion

Shih-Ta Chen's contributions to cancer treatment through his patents demonstrate his dedication to improving patient outcomes. His innovative approaches, particularly in nucleic acid-drug complexes and nanoparticle delivery systems, position him as a key figure in the ongoing fight against cancer.